STYLAGE® M BI-SOFT® with Lidocaine

Key Uses of STYLAGE M BI-SOFT with Lidocaine

• This product can be applied on both women and men to reduce the appearance of medium to deep lines and wrinkles around the face.

• Apply it around the forehead, temples, nose, cheeks, nasolabial folds, and marionette lines.

• Improve the size and shape of the lips.

• Hydrate the tissue and restore lost volume to the sunken skin.

• Numb the pain with lidocaine.

• Smooth out the skin surface with an authentic glow-up.

Manufacturing Information for STYLAGE M BI-SOFT with Lidocaine

Laboratoires VIVACY from France is the manufacturer of STYLAGE products and proprietary technologies, such as BI-SOFT syringe and the IPN-Like technology. VIVACY beauty and health products are distributed to over 80 countries around the world.

Expected Benefits and Results of the Treatment

• IPN-Like Technology allows the manufacturer to accurately define each product’s viscoelastic properties that influence the ability to lift the skin, provide mechanical support, and spread the HA gel.
• Cross-linked hyaluronic acid restores lost volume to the flaccid and sunken skin and provides much-needed hydration. This HA gel is fully biocompatible and biodegradable with human skin.
• Mannitol is an antioxidant that prolongs the absorption process of hyaluronic acid and the moisturising benefits of the gel.
• BI-SOFT syringe ensures a precise and controlled injection procedure by incorporating the soft, non-slip plastic that has a different colour for each product.
• Lidocaine is used as an anaesthetic to reduce the pain and discomfort during the injection procedure.
• This formula reduces the risk of side effects and allergic reactions, and the procedure itself requires no downtime for the patients.

STYLAGE M BI-SOFT with Lidocaine Key Ingredients and Device Features

• Cross-linked hyaluronic acid 20 mg/g

• Lidocaine hydrochloride 0.3%

• Mannitol 0.9%

• Phosphate buffer pH 7.2

Device properties:

• BI-SOFT syringe
• IPN-Like technology

Included Items or Accessories

• 2 x 1 ml prefilled syringes
• 4 x 30G½” needles
• Traceability labels
• Package insert

Administration Method for STYLAGE M BI-SOFT with Lidocaine

• STYLAGE M BI-SOFT with Lidocaine requires professional application.
• Discuss the treatment expectations with your clients.
• Check their medical records for any conditions that may have a negative impact on the procedure and the patient’s health.
• Clean and disinfect the area of the treatment.
• Inject this filler into mid to deep dermis around the face or into the lip mucosa using a 30G½” needle.
• Observe the patient for any side effects and instruct them about proper post-treatment care.

Guidelines for Proper Aftercare

• Avoid tanning salons, direct sunlight, and UV rays for several days.
• Stay away from places with moisture and water, like pools, saunas, bathhouses, and beaches.
• Do not expose yourself to extremely cold or hot conditions.
• Do not apply makeup or cosmetic products for 24 hours.
• Avoid ingesting known blood thinners such as alcohol and aspirin.
• Apply high SPF sunscreen for two weeks post-treatment.

Duration of STYLAGE M BI-SOFT with Lidocaine Effects

The benefits of the STYLAGE M BI-SOFT with Lidocaine treatment are expected to last from 6 to 2 months. Depending on the patient’s age, skin type, and lifestyle, extra maintenance procedures might be recommended.

Potential Risks and Side Effects

• Swelling
• Redness
• Bruising
• Pain
• Tenderness

The common side effects of the STYLAGE M BI-SOFT with Lidocaine do not last longer than a few days. If the unwanted effects do last longer than a week, or if the patients experience allergic reactions, infections, haematomas, necrosis, abscesses, and granulomas, they should seek immediate medical attention.

STYLAGE M BI-SOFT with Lidocaine Treatment Contraindications

• Underage individuals.
• Nursing or pregnant women.
• Anyone with known allergies to hyaluronic acid or lidocaine.
• Anyone who underwent a recent medical procedure and is on medications.
• Patients with autoimmune disorders.
• Individuals with infections near the injection site.